

Mr. H - Metastatic Gastric Adenocarcinoma (Lung, Liver)

Ng Boon Huat
Sarawak General Hospital
Sarawak, Malaysia

Disclosures

- No disclosures

History (I)

- 60 year old man with no medical illness
- Presented with new onset gastritis for the past 4 months, partially relieved by esomeprazole but having frequent exacerbations
- Noted weight loss from 72kg to 63kg, loss of appetite and early satiety
- Patient performance status was ECOG 1

History (II)

- OGDS and colonoscope done (in private hospital)
 - Colonoscope: No abnormality detected
 - OGDS: 4cm ulcerative lesion noted at gastric fundus. Multiple biopsies taken. Minimal bleeding.
- Histopathology report:
 - Adenocarcinoma, intestinal type. HER2 overexpressed.
- CT staging was arranged and noted:
 - Gastric fundus cancer with regional lymphadenopathy
 - Multiple liver and lung metastasis

Management

- Patient was counselled and agreeable for palliative chemotherapy + trastuzumab as per Trastuzumab for Gastric Cancer (ToGA) trial:
 - IV cisplatin 80 mg/m² D1 only, IV 5-FU 800 mg/m² D1-5; every 3 weeks for 6 cycles,
 - IV trastuzumab 8/6 mg/kg D1 only, every 3 weeks until progression disease (self purchase)
- CT restaging post cycle-3 noted partial response in both lung and liver lesions.
 - Clinically, he was tolerating treatment and his weight increased from 62kg to 65 kg.
- Patient completed 6 cycles combination treatment and followed by trastuzumab alone for another 7 cycles (total 13 cycles). He stopped treatment due to financial constrain.
- CT restaging 3 months after stopping treatment - stable disease

Point of discussions

- Any role of maintenance fluoropyrimidine if patient unable to afford trastuzumab
- Best and cost effective second line treatment options (besides biologics)
- Any immunotherapy improve treatment outcomes

Combination Chemotherapy

- 1999: Japanese phase II study, combination (doublet) chemotherapy (Irinotecan+Cisplatin): median OS to **10.4 months** (N Boku, 1999).
- 2006: V325 study group (large phase III study): DCF vs CF regime: **median OS 9.2 months vs 8.6 months** (E Van Cutsem, 2006).
- 2008: Korean phase II trial, combination of irinotecan + 5FU with irinotecan + cisplatin: **median OS was 10.7 months vs 10.5 months** (SH Park, 2008)
- 2008: REAL-2 (large phase III study) comparing triplet chemotherapy (ECF, ECX, EOF, EOX) reported: **median OS ranging from 9.9m ECF regime to 11.2 months** for EOX regime (D Cunningham, 2008).
- 2009: ML 17032 trial with capecitabine/ cisplatin vs 5-FU/ cisplatin: **median OS 10.5 months vs 9.3 months** (YK Kang, 2009)
- 2015: Median overall survival was **18.8 months** and **12.6 months** with modified DCF (mDCF) and DCF, respectively (Shah MA, 2015).

Combining Chemotherapy with Biologic Therapy

- 2010: ToGA clinical trial with T-CF vs CF: **median OS** was 13.8 months vs 11.1 months (16 months vs 11.8 months in subset analysis with Her2 over-expressed only), (YJ Bang, 2010).
- AVAGAST trial comparing Avastin + Cisplatin (C) + Xeloda (X) with CX regime: **median OS**: 12.1 months and 10.1 months, respectively (A Ohtsu, 2011)
- 2016 CGOG1001 (phase II, small sample size) trial with T-XO with: **median OS** of 19.5 months (J Gong, 2016)